You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Dow
Express Scripts
Boehringer Ingelheim
Mallinckrodt

Last Updated: April 1, 2020

DrugPatentWatch Database Preview

ACTINEX Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Actinex, and when can generic versions of Actinex launch?

Actinex is a drug marketed by Univ Az Cancer Ctr and is included in one NDA.

The generic ingredient in ACTINEX is masoprocol. There is one drug master file entry for this compound. Additional details are available on the masoprocol profile page.

Summary for ACTINEX
US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: 31
Patent Applications: 4,511
DailyMed Link:ACTINEX at DailyMed
Drug patent expirations by year for ACTINEX
Synonyms for ACTINEX
(R*,S*)-4,4'-(2,3-Dimethylbutane-1,4-diyl)bispyrocatechol
1,2-Benzenediol, 4,4'-((2R,3S)-2,3-dimethyl-1,4-butanediyl)bis-, rel-
1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-
27686-84-6
4-[(2R,3S)-4-(3,4-dihydroxyphenyl)-2,3-dimethyl-butyl]benzene-1,2-diol
4-[(2R,3S)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
4-[(2S,3R)-3-[(3,4-dihydroxyphenyl)methyl]-2-methylbutyl]benzene-1,2-diol
4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol)
4,4'-((2R,3S)-2,3-dimethylbutane-1,4-diyl)dibenzene-1,2-diol
4,4'-((2R,3S)-rel-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol)
4,4'-[(2R,3S)-2,3-Dimethyl-1,4-butanediyl]biscatechol
4,4'-[(2R,3S)-2,3-Dimethylbutane-1,4-diyl]di(benzene-1,2-diol)
686B846
7BO8G1BYQU
Actinex (TN)
AKOS016014015
API0001379
AX8137243
AX8267578
BDBM22372
BIDD:ER0127
C18H22O4
CAS-27686-84-6
CCG-204959
CHEBI:73468
CHEMBL313972
CHX 100
CHX-100
D04862
DB00179
DSSTox_CID_25178
DSSTox_GSID_45178
DSSTox_RID_80726
DTXSID5045178
EINECS 248-606-6
erythro-nordihydroguaiaretic acid
EU-0100877
HMS3262P15
INSM-18
Lopac-N-5023
Lopac0_000877
LP00877
LS-174190
Masoprocol
Masoprocol (Nordihydroguaiaretic)
Masoprocol (USAN/INN)
Masoprocol [USAN:INN]
Masoprocolum
Masoprocolum [INN-Latin]
meso-1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane
meso-2,3-bis(3,4-dihydroxyphenylmethyl)butane
meso-4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
meso-4,4'-(2,3-dimethyl-1,4-butanediyl)bis(pyrocatechol)
meso-4,4'-(2,3-Dimethyltetrameth-ylene)dipyrocatechol
meso-4,4'-(2,3-Dimethyltetramethylene)dipyrocatechol
meso-beta,gamma-dimethyl-alpha,delta-bis(3,4-dihydroxyphenyl)butan
meso-NDGA
meso-Nordihydroguaiaretic acid
N 5023
NCGC00015741-01
NCGC00015741-02
NCGC00015741-03
NCGC00015741-06
NCGC00015741-06!NORDIHYDROGUAIARETIC ACID
NCGC00015741-07
NCGC00094201-01
NCGC00094201-02
NCGC00094201-03
NCGC00094201-04
NCGC00094201-05
NCGC00261562-01
Nordihydroguaiaretic acid (meso-form)
Nordihydroguaiaretic acid from Larrea divaricata (creosote bush)
Nordihydroguaiaretsaure
NSC-4291
NSC-682984
Q6783851
SCHEMBL3818
SR-01000076028
SR-01000076028-1
TNP00263
Tox21_110210
Tox21_500877
UNII-7BO8G1BYQU
Z-3136
ZINC12342

US Patents and Regulatory Information for ACTINEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Univ Az Cancer Ctr ACTINEX masoprocol CREAM;TOPICAL 019940-001 Sep 4, 1992 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Dow
Express Scripts
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.